DANIEL TEPER, CHIEF EXECUTIVE OFFICER
Dr. DANIEL TEPER, CHIEF EXECUTIVE OFFICER
Dr. Daniel Teper is the founder and CEO of IMMUNE Pharmaceuticals. He was the Managing Director for North America at Bionest Partners, a global Strategy Consulting firm advising pharmaceutical and public biotechnology companies and previously a New York based Partner at ISO Healthcare Consulting (now part of Deloitte Monitor). Daniel started his career at Novartis Global Headquarters in Basel and then in the United States where he had growing responsibilities in sales, marketing and new product development. He held senior executive positions in Europe, first at GSK as Head of Commercial Operations for Glaxo France and then as President and President of Laboratoires Delagrange through the acquisition by Synthelabo (now part of Sanofi). He then became Global President HAVAS Health, a leading marketing and communication group, where he helped launch multiple industry blockbusters. Daniel was a cofounder of Novagali (NYSE Euronext: NOVA), which was acquired by Japan’s Santen. Daniel holds a Doctor of Pharmacy degree (PharmD) from Paris XI University and an MBA from INSEAD.
DR. MONICA E. LUCHI, EXECUTIVE VICE PRESIDENT GLOBAL DRUG DEVELOPMENT, CHIEF MEDICAL OFFICER
Dr. Monica E. Luchi is currently the Chief Medical officer for New York based biotech company Immune Pharmaceuticals, and Executive Vice President of Global Drug Development. She is a Board certified rheumatologist with 15 years industry experience at a mix of both large pharmaceutical and small biotech companies. Prior to joining Immune, Dr. Luchi held senior immunology and inflammation positions at Novartis, Incyte and most recently, Mesoblast, where she has led cross-functional teams and drove strategy across a variety of therapeutic areas and phases of development. In addition, Dr. Luchi has helped to drive the business interests of the biotech companies where she worked in order to engage development partners and to strengthen financial assets to support further progress of the companies’ development activities. She is adjunct Clinical Assistant Professor on faculty at the University of Pennsylvania where she did her fellowship, and continues to see patients there one half day per week. She has recently served on a local chapter board for the Healthcare Businesswoman’s Association. Dr. Luchi obtained a BA in Biology and in Health Science Policy at the University of Maryland, Baltimore Co. Campus, received her MD from Northeastern Ohio Universities, College of Medicine, and an MBA with a concentration in healthcare from George Washington University.
DR. MIRI BEN-AMI, PRESIDENT, IMMUNE ONCOLOGY PHARMACEUTICALS INC AND IMMUNE PHARMACEUTICALS LTD.
Miri Ben-Ami’s background includes more than 15 years in executing broad management and drug development responsibilities for the healthcare industry. Most recently, she served as the CEO for Aposense Ltd., a clinical stage public biotech company developing therapeutics and molecular imaging diagnostics in the field of oncology. Under her leadership, the company refocused its drug pipeline, entered into partnerships with big pharma, and received approval from the FDA for accelerated development of its lead compound. Before that, Miri held senior leadership roles during her 9-year tenure at Teva Pharmaceuticals. As Global Head of Neurology, Miri spearheaded development strategies for Copaxone, a lead immunomodulator in multiple sclerosis, underlying the successful expansion of the product’s indications and market. Currently, Miri serves on the governing board of the Israeli Public Companies Association, as Chairperson of the organization’s life-sciences division. Miri obtained her B.Sc.(Hon.) degree in Medical Biochemistry and her M.D. degree from the University of the Witwatersrand, Johannesburg, and gained clinical experience during her residency in Obstetrics and Gynecology in the UK and Israel.
JOHN MILITELLO, VP FINANCE, CONTROLLER, CHIEF ACCOUNTING OFFICER AND PRINCIPAL FINANCIAL OFFICER
John joined the Company’s in April 2015 as our Executive Director of Finance and Corporate Controller. Prior to that, Mr. Militello was an Assistant Controller with Retrophin, Inc., a San Diego based biotech company, and the Manager, External Reporting & Compliance at Volt Information Sciences, Inc., a publicly traded staffing company. Prior to Volt Information Sciences, Inc., Mr. Militello was a Senior Manager with BDO USA, LLP serving multi-national SEC registrants. Mr. Militello is a Certified Public Accountant and earned his Bachelor of Science degree in Accounting from St. Joseph’s College.
DR. JEAN KADOUCHE, SVP, SCIENTIFIC DEVELOPMENT
Co-founder of Immune Pharmaceuticals and a scientific advisor focusing on the development and application of novel antibody technologies, including fully human antibody generation, bi-specific antibodies and antibody drug conjugates. With 25 years of experience in the development of mAbs in both academia and industry, Dr. Kadouche was the developer of the bispecific antibody platform and co-developer (with Prof. Simon Benita) of the NanoMAbs technology – both licensed by Immune Pharmaceuticals from Atlante Biotech and the Hebrew University of Jerusalem respectively. Dr. Kadouche is the former CEO of MAT BioPharma, an antibody company where Kadouche developed and partnered several clinical and pre-clinical antibodies. He is also the founder of Clonatec and a co-founder of Novagali (NYSE Euronext: NOVA) and has been an advisor to SangStat, Roche, Merck AG and J&J. Dr. Kadouche holds a PhD in immunology from the Pasteur Institute and was an Assistant Professor at St Louis Hospital. He has about 100 publications and registered over 15 patents which have led to company creations.
DR. MARK LEVITT, SVP, CLINICAL AFFAIRS, ONCOLOGY
Mark L. Levitt, MD, PhD is a Board Certified Medical Oncologist and has a strong academic background in both basic and clinical oncology research as well as extensive experience in small and big pharma. His area of focus in the pharmaceutical industry has been in clinical development, business development and clinical and scientific evaluation and strategy.
Following his residency, he did his fellowship in Medical Oncology at the National Cancer Institute (NIH) and subsequently became Director of the University of Pittsburgh Cancer Institute Pulmonary Oncology Program. During this time he was co-PI on one of the first SPORE grants in lung cancer and a leader in ECOG, serving on several steering committees as well as the Laboratory Science Advisory Committee. In 2006, Mark joined Teva Pharmaceutical Industries Ltd. as the Global Clinical Oncology Platform Leader in Innovative R&D following which he became the Global Head of the Oncology Therapeutic Area and helped lead Teva to the establishment of an Oncology Franchise with the acquisition in 2011 of Cephalon.